Boehringer Ingelheim convinces NICE that Pradaxa is cost-effective
This article was originally published in Scrip
Boehringer Ingelheim has convinced NICE, the health technology appraisal institute for England and Wales, to recommend its blood thinner Pradaxa (dabigatran) for use on the NHS. In August, the institute was undecided about the drug and wanted more information. But final draft guidance published 1 November 2011 says that the drug is a cost-effective alternative to warfarin, the drug that Pradaxa is designed to replace.